GSK Lamictal monotherapy for seizures
Executive Summary
GlaxoSmithKline's Lamictal (lamotrigine) approved by FDA Jan. 14 for use as monotherapy in the treatment of partial seizures in patients 16 years and older. Originally approved in December 1996 as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, Lamictal has been part of GSK's plan to fill in its nearer-term pipeline through line extensions (1"The Pink Sheet" Dec. 15, 2003, p. 29)...
You may also be interested in...
GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come
GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.